Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clonidine extended release - Sollis Therapeutics

Next Previous
Drug Profile

Clonidine extended release - Sollis Therapeutics

Alternative Names: Clonidine micropellets - Sollis Therapeutics; STX-015

Latest Information Update: 10 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sollis Therapeutics
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Behavioural disorder therapies; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Non-opioid analgesics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Radiculopathy; Sciatica

Most Recent Events

  • 22 Apr 2024 Sollis Therapeutics terminates the SERENITY CM phase III trial in Radiculopathy (Treatment-experienced) in USA (Injection, Controlled release) due to loss of funding (NCT05614648)
  • 19 Jun 2023 Phase-III clinical trials in Radiculopathy (Treatment-experienced) in USA (Injection, Controlled release) (NCT05614648)
  • 17 Nov 2022 Sollis Therapeutics plans a phase III trial in Radiculopathy in April 2023 (Epidural, Injection) (NCT05614648)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top